Core Insights - Avicanna Inc. has announced positive preclinical results for its novel Powder Drug Delivery System (PwdRx), which enhances the bioavailability and absorption of cannabinoids, and has filed a provisional patent application with the USPTO [1][2][6] Group 1: PwdRx Technology - The PwdRx platform addresses formulation challenges of lipophilic cannabinoids, improving water solubility, bioavailability, and onset of action [2][6] - In preclinical studies, PwdRx showed 74% higher bioavailability, 63% faster peak plasma levels, and 134% higher peak plasma concentration compared to MCT oil formulations [3][5] - The technology supports long-term stability and manufacturing versatility, allowing for scalable production in various formats such as tablets, capsules, and pouches [6] Group 2: Clinical Applications - The provisional patent covers the use of PwdRx in treating pain and inflammation-related conditions, including rheumatoid arthritis, osteoarthritis, neuropathic pain, fibromyalgia, migraine, and multiple sclerosis [6] - The platform aims to provide healthcare providers with greater flexibility in tailoring treatment options for patients [6] Group 3: Company Positioning - The advancement of the PwdRx platform strengthens Avicanna's intellectual property portfolio and positions the company as a leader in cannabinoid delivery technology [7] - Avicanna is focused on the commercialization of cannabinoid-based products and has developed over thirty proprietary products for the medical and pharmaceutical markets [8]

Core Insights - Avicanna Inc. reported Q3 2025 results, highlighting continued revenue growth and advancements in its biopharmaceutical strategy focused on cannabinoid-based products [1][2]. Financial Performance - Revenue for Q3 2025 reached $6.40 million, with a total of $18.88 million for the nine-month period ending September 30, 2025. Canadian revenue increased by 4%, marking two consecutive quarters of growth, while international revenue rose by approximately 6% compared to Q2 2025 [5]. - Gross profit was $3.15 million for Q3 2025, resulting in a gross margin of 49%, down from 57% in the prior year due to non-recurring costs and a Canada Post strike. The nine-month gross margin improved slightly to 52% from 50% in the previous period [5]. - The adjusted EBITDA loss for Q3 2025 was $0.79 million, a decrease from the same period in 2024, while the nine-month adjusted EBITDA loss was $0.61 million, showing improvement from $0.72 million in 2024 [5]. Commercial Advancements - Canadian commercial advancements led to record sales of 62,987 units in Q3 2025, a 39% increase compared to Q3 2024. The company had 52 commercial SKUs and 174 listings, representing 29% growth from Q3 2024 and 18% growth from Q2 2025 [5]. - The MyMedi.ca platform experienced growth due to medical affairs initiatives, and the B2B Medical unit saw a 113% increase in products sold. The Adult-Use business expanded into three new provinces and territories [5]. Intellectual Property and Collaborations - The United States Patent & Trademark Office issued patent No. US 12,343,315 B2 for a topical gel formulation containing cannabinoids, aimed at treating skin conditions such as acne and wrinkles [5]. - Avicanna's subsidiary completed the export of CBD-dominant cannabis flower to Switzerland, marking the first export of organic certified flower and expanding the Aureus portfolio in international markets [5]. New Product Launches - Avicanna LATAM SAS and Harrington Wellness launched the re+PLAY CBD wellness brand in the U.S., featuring products that utilize Avicanna's patented CBD formulations [6].

Core Insights - Avicanna Inc. reported Q2 2025 results, highlighting growth in its commercial channels and achieving positive adjusted EBITDA for the first half of 2025, indicating operational efficiency and financial discipline [2][5]. Financial Highlights - Revenue for Q2 2025 was $6.16 million, a 1% increase year-over-year, while revenue for the six-month period was $12.48 million, reflecting a 1% decrease compared to the same period in 2024 [5]. - Gross profit for Q2 was $3.13 million, with a gross margin of 51%, and for the six-month period, gross profit totaled $6.73 million with a margin of 54%, up from 47% in the prior-year periods [5]. - Adjusted EBITDA showed a loss of $0.25 million for Q2 but a gain of $0.18 million for the six-month period, marking an improvement from losses of $0.44 million and $0.42 million in the same periods of 2024 [5]. Corporate Highlights - The company expanded its product offerings, ending Q2 with 50 commercial SKUs and 147 listings, representing a 19% increase in SKUs and a 9% increase in listings from Q1 2025 [5]. - Avicanna sold 50,789 units in Q2, a 21% increase compared to the same period in 2024 [5]. - The company announced a sponsorship for a Phase II clinical study on osteoarthritis pain, which is its first placebo-controlled, blinded randomized multicenter trial [5]. - A symposium on cannabinoid-based medicine was held in June 2025, focusing on research and clinical applications, attended by key opinion leaders and healthcare providers [5]. - Avicanna received a new patent from the US Patent and Trademark Office for a topical cannabinoid composition aimed at treating skin conditions [5][6].